| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
23 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-46 |
| Cash Flow (TTM) (Millions $) |
34 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Celyad Oncology SA is a biopharmaceutical company based in Belgium. It focuses on the development of innovative CAR-T cell therapies for the treatment of cancer. CAR-T cell therapy is a cutting-edge immunotherapy approach that uses a patient's own immune cells to recognize and destroy cancer cells. Celyad Oncology's unique CAR-T platform, known as CAR-T NKR-2, is designed to target a protein called NKG2D, which is found on the surface of cancer cells. By targeting NKG2D, CAR-T NKR-2 aims to enhance the immune system's ability to recognize and eliminate cancer cells. The company is dedicated to advancing its pipeline of CAR-T therapies for multiple types of cancer, with a focus on improving patient outcomes and quality of life.
Company Address: Rue Edouard Belin 2 Mont-Saint-Guibert 1435
Company Phone Number: 10 394 100 Stock Exchange / Ticker: NASDAQ CYAD
|
%
5.85% 